Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Med Chem ; 63(15): 8584-8607, 2020 08 13.
Artículo en Inglés | MEDLINE | ID: mdl-32667798

RESUMEN

The C-C chemokine receptor 4 (CCR4) is broadly expressed on regulatory T cells (Treg) as well as other circulating and tissue-resident T cells. Treg can be recruited to the tumor microenvironment (TME) through the C-C chemokines CCL17 and CCL22. Treg accumulation in the TME has been shown to dampen the antitumor immune response and is thought to be an important driver in tumor immune evasion. Preclinical and clinical data suggest that reducing the Treg population in the TME can potentiate the antitumor immune response of checkpoint inhibitors. We have developed small-molecule antagonists of CCR4, featuring a novel piperidinyl-azetidine motif, that inhibit the recruitment of Treg into the TME and elicit antitumor responses as a single agent or in combination with an immune checkpoint blockade. The discovery of these potent, selective, and orally bioavailable CCR4 antagonists, and their activity in in vitro and in vivo models, is described herein.


Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacología , Azetidinas/química , Azetidinas/farmacología , Receptores CCR4/antagonistas & inhibidores , Animales , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapéutico , Azetidinas/farmacocinética , Azetidinas/uso terapéutico , Línea Celular Tumoral , Perros , Humanos , Macaca fascicularis , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Piperidinas/química , Piperidinas/farmacocinética , Piperidinas/farmacología , Piperidinas/uso terapéutico , Receptores CCR4/inmunología , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA